Abstract
INTRODUCTION
Nonalcoholic fatty liver disease (NAFLD) is charac terized by excess triglyceride accumulation and lobular inflammatory infiltration and is a leading cause of most chronic liver diseases in European, Asian-Pacific, and American patients [1] . According to the diagnosis and management guidelines, hyperlipidemia (e.g., hypertriglyceridemia or hypercholesterolemia) has been identified as one of the most important risk factors for NAFLD [2] . Approximately 50% of patients with hyperlipidemia have ultrasonographic evidence of fatty infiltration in the liver [3] . Patients with a spectrum of NAFLD, ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), show prevalence of dyslipidemia, including increased serum triglycerides and lowdensity lipoprotein (LDL), and low levels of highdensity lipoprotein cholesterol (HDLC) [4] . Thus, the lipidemic properties are closely associated with the initiation and progression of NAFLD.
Recently, genomewide association analysis and clinical investigations have found that single nucleotide polymorphisms (SNPs) of patatinlike phospholipase domain containing 3 (PNPLA3) (e.g., rs738409, rs 1010023, rs2281135, rs139051 and rs2294918) underlie the genetic susceptibility of NAFLD, independent of gender, age and ethnic background [511] . Functional studies have highlighted that adiponutrin, the encoded product of PNPLA3, is a crucial regulator of lipid meta bolism in the liver via its activities on triacylglycerol lipase and acyl glycerol Oacyltransferase [12] . Given the central role of the liver in systemic lipid homeostasis, these lossoffunction SNPs in PNPLA3 are suggested to predispose individuals to NAFLD, probably by dy sregulation of hepatic and serum lipid profiles [4] . This lipidmetabolismregulating role of PNPLA3 SNPs has been confirmed in the liver of NAFLD patients [13] . However, understanding of the SNPspecific impact on serum lipids and their correlation with pathological characteristics is still limited and controversial [1417] . We therefore stratified Chinese Han patients with biopsyproven NAFLD by genotyping their PNPLA3 SNPs. Ultrahigh performance liquid chromatogra phytandem mass spectrometry (UPLCMS/MS) was used to characterize the effects of PNPLA3 SNPs on serum lipidomics of NAFLD patients. Correlation analysis uncovered the association of PNPLA3related lipid profile and hepatic pathological characteristics by assessment of steatosis, activity and fibrosis (SAF). Finally, variantbased scoring of steatosis, ballooning, inflammation, and liver fibrosis was performed to reveal the actions of lipidomicsaffecting PNPLA3 SNPs on NAFLD-specific pathological alterations.
MATERIALS AND METHODS

Study population
Thirtyfour Chinese Han patients with biopsyproven NAFLD were enrolled from Shanghai Xinhua Hospital (n = 17), Zhengxing Hospital (n = 8) and Tianjin Hospital of Infectious Diseases (n = 9) between January 2012 and June 2013. The exclusion criteria were as follows: historic or current high alcohol consumption equivalent to > 20 g/d for men and > 10 g/d for women [18, 19] , viral hepatitis, druginduced liver disease, Wilson's disease, autoimmune liver diseases and other diseases that lead to steatosis. The study was approved by the Xinhua Hospital Research Ethics Committee, and informed consent was obtained from all patients.
Anthropometric and biochemical assessments
The baseline data of age (41.03 ± 14.81 years), gender, height (167.44 ± 7.82 cm), weight (75.34 ± 9.49 kg), and body mass index (BMI) (26.90 ± 3.13) were characterized for the study population. Fasting blood samples were collected from the NAFLD patients, and a multichannel automatic analyzer (Advia 1650; Bayer, Moss, Norway) was used to test biochemical indexes of alanine aminotransferase (58.33 ± 33.89 U/L), aspartate aminotransferase (24.05 ± 28.63 U/L), alkaline phosphatase (101.90 ± 110.49 U/L), and γ-glutamyltransferase (115.73 ± 278.59 U/L). Fasting blood glucose (42.70 ± 28.07 μIU/mL), total cholesterol (4.70 ± 0.61 mg/dL), and triglyceride (1.70 ± 0.68 mg/dL) were subjected to assessment using Wako Bioproducts (Wako Pure Chemical Industries, Richmond, VA, United States).
Hepatic histopathological assessment
Liver samples from each NAFLD patient were obtained by needle biopsy after obtaining informed consent. Liver tissues were fixed in formalin, paraffin embedded, and 5-μm sections were cut. Both hematoxylin and eosin and Masson's trichrome staining were used for pathological characterization, including hepatocyte steatosis, lobular inflammation, ballooning, and liver fibrosis according to the SAF scoring method [2022] , by three pathologists who were not aware of the study.
Genotyping of PNPLA3 SNPs
Blood samples from NAFLD patients were treated as follows: (1) [23] .
UPLC-MS/MS
After 12h fasting, serum lipidomics of the enrolled NAFLD patients were analyzed with a combination of UPLC (Waters, Milford, MA, United States) and Triple TOF 5600 mass spectrometer (AB SCIEX, Framingham, MA, United States) [24] . The column temperature was set to 55℃. The ratios of acetonitrile/water (mobile phase A) and propanol/acetonitrile (mobile phase B) were 3/2 and 9/1, respectively, with 10 mmol/L ammonium acetate added to all mobile phases. The elution gradient program was carried out as follows: 01.5 min: 32% B; 1.514 min: 85% B; 15.515.6 min: 97% B; 15.6 18 min: 97% B; 1820 min: 32% B (flow rate: 0.26 mL/min). MS was applied by electrospray ionization operating in the positive and negative ion modes. The temperature of the interface heater was 600℃ (-) and 500°C (+), with 4500 V (-) and 5500 V (+) ion spray voltage. The declustering potential was 100 V (-) and 100 V (+), and collision energy was 10 V (-) and 10 V (+). Thirteen quality control (QC) samples, being randomly inserted into the sequence, were analyzed for data precision. The raw data obtained from UPLCMS/MS by Analyst TF 1.6 software (AB SCIEX) were subjected to identification of lipid composition using LipidView/PeakView and quantification of lipid concentrations using MultiQuant 2.0. The relative standard deviation (RSD) of 239 serum lipids in QC samples was evaluated against the internal standards.
Statistical analysis
The clinical data were expressed as mean ± SD (continuous, normally distributed variables) or medians (interquartile range) (discontinuous, nonnormally distributed variables). Differences in serum lipidomics among the groups of PNPLA3 SNPs were investigated by unpaired Student's independent t tests. Correla tion analysis of phospholipid metabolite profile and hepatic pathological characteristics was assessed by Spearman's correlation. The MannWhitney U test was performed to evaluate the differences in pathological grading among groups of PNPLA3 SNPs. SPSS version 19.0 (SPSS Inc., Chicago, IL, United States) was used for statistical analysis with a twoside significant criterion at P < 0.05.
RESULTS
PNPLA3 SNPs associated with serum lipidomics in NAFLD patients
With the stable distribution and limited RSD of QC samples ( Figure 1 and Table 1 ), an obvious association of PNPLA3 SNPs (rs139051, rs738408, rs738409, rs2072906, rs2294918, rs2294919 and rs4823173) and serum lipidomic characteristics was observed in Chinese Han NAFLD patients by combination of PNPLA3 genotyping and UPLCMS/MS (Table 2 ). In detail, these PNPLA3 SNPs significantly correlated to the serum level of various members of cholesteryl ester (CE), free fatty acid (FFA), lyso phosphatidylcholine (LPC), lysophosphatidylcholine plasmalogen (LPCO), lysophosphatidylethanolamine Luo JJ et al . PNPLA3 rs139051 is associated with phospholipids and liver inflammation (LPE), phosphatidylcholine (PC), choline plasmalogen (PCO), phosphatidylethanolamine (PE), ethanolamine plasmalogen (PEO), and triacylglycerol (TAG) ( Table 2 ).
PNPLA3 rs139051 and rs2294918 exerted upregulatory effects on LPCs and LPCOs
PNPLA3 rs139051 and rs2294918, with their effects on 12 and 22 different serum lipids, respectively, dominated the PNPLA3 SNPlipidomics association (Table  2) (Table  3) . Nevertheless, there was lower serum levels of LPE 22:6, PC 32:1, PE 34:0, PE 34:2, PE 36:2, PE 36:4, PE 38:4, PE 38:5, PE 38:6, PE 40:5 and PE 40:6 in these patients (Table 3) .
High levels of LPCs and LPCOs demonstrated a correlation with low-grade hepatic inflammation
To shed light on the influence of PNPLA3 SNPrelated lipidomic characteristics, correlations of phospholipid metabolites and NAFLD-specific pathological disorders (hepatocyte steatosis, lobular inflammation, ballooning, and liver fibrosis) were analyzed. Various LPCs (LPC 17:0, LPC 18:0, LPC 20:0, LPC 20:1 and LPC 20:2) and LPCOs (LPC O16:1 and LPC O18:1) showed negative correlations with the grade of lobular inflammation. The serum levels of these phospholipid metabolites were high in NAFLD patients with the A/A genotype at PNPLA3 rs139051 and/or the G/G genotype at rs2294918. Most of them shared similar Spearman's rank correlation coefficients (Table 4 ). In contrast, pathological indexes other than lobular inflammation correlated to neither highlevel phospholipid metabolites (LPCs and LPCOs) nor lowlevel ones (LPEs, PC 32:1, PEs and PEO 36:5) in these NAFLD patients (Table 4) . Given their impact on the serum profile of phospholipid metabolites, both PNPLA3 rs139051 and rs2294918 are proposed to act in hepatic inflammation of NAFLD by targeting, at least to a large extent, LPCs and LPCOs.
Low-grade hepatic inflammation occurred in NAFLD patients with the A/A genotype at PNPLA3 rs139051
After the stratification of NAFLD patients by PNPLA3 Table 4 Phospholipid metabolites correlated with pathological characteristics of nonalcoholic fatty liver disease
Luo JJ et al . PNPLA3 rs139051 is associated with phospholipids and liver inflammation genotypes, comparison of steatosis, lobular inflam mation, ballooning, and liver fibrosis was carried out to assess the pathological role of PNPLA3 rs139051 and rs2294918. By the SAFbased scoring, the A/A genotype at PNPLA3 rs139051 conferred significantly lower lobular inflammation than the A/G + G/G ge notypes (Figure 2 ). However, PNPLA3 rs139051 did not seem to exert any significant impact on NAFLD specific steatosis, ballooning, and fibrosis ( Figure 2 ). NAFLD patients with PNPLA3 rs2294918, another SNP related to the inflammationassociated phospholipid metabolites, showed a comparable grade in each of these pathological indexes regardless of genotype ( Figure 3 ).
DISCUSSION
PNPLA3 is the liverenriched member of the PNPLA family, which is located on the membrane of lipid droplets and endoplasmic reticulum in hepatocytes [25, 26] . Its conserved patatinlike domain demonstrates hydrolase activity against TAG, diacylglycerol and monoacylglycerol [15] . Activities of thioesterase and acylglycerol transacylase reflect the other aspects of the lipometabolic action of PNPLA3 [15] . PNPLA3 was recently identified to promote the transfer of verylongchain polyunsaturated fatty acids from TAG to phospholipids [27] . These effects shed light on an important regulatory role of PNPLA3 in lipid homeostasis [13] , which is supposed to be affected by PNPLA3related genetic variants.
In the present study, genotypebased, widespread effects of PNPLA3 SNPs in lipid profiles were found in the sera of NAFLD patients from Northern (Tianjin), Central (Shanghai) and Southern China (Zhangzhou, Fujian). Being similar to previous reports [13, 28, 29] , members of TAG, CE and FFA were identified in the differential serum lipids associated with PNPLA3 SNPs (e.g., rs738408, rs738409, rs2072906, rs2294919 and rs4823173). In contrast, PNPLA3 rs139051 and rs2294918 primarily exerted their lipidomic impact on phospholipid metabolites. LPCs, LPCOs and PEs were confirmed to dominate the differential serum lipids because of their high abundance. Therefore, dysregulation of phospholipid metabolite profile reflects the major role of PNPLA3 SNPs in serum lipidomics.
To gain further insight into the PNPLA3related phospholipid characteristics, differences in serum levels of LPC, LPCO and PE were analyzed between various genotypes of PNPLA3 rs139051 and rs2294918. NAFLD patients with the A/A instead of A/G + G/G genotype at PNPLA3 rs139051 exhibited significantly higher levels of LPCs and LPCOs. The G/G, but not the A/A + A/G, genotype of PNPLA3 rs2294918 also predisposed NAFLD patients to statistical elevation of serum LPCs and LPCOs. Various types of LPCs (e.g., LPC 17:0 and LPC 18:0) have been shown to play a critical role in the spectrum of NAFLD [30, 31] . Their reduction in blood samples was detected in patients with 1 biopsyproven hepatic steatosis [30] . Similarly, significant decreases in serum palmitoyl, stearoyl and oleoyl LPC were obtained in an experimental rodent model of NASH [32] . In contrast, uptake of LPC metabolite (PC) ameliorates the hepatic injury of NAFLD with a reduction of serum aspartate aminotransferase and alanine aminotransferase [33] . Given the similarity in LPC and LPCObased lipid metabolism [32, 3437] , PNPLA3 rs139051 and rs2294918 are suggested to protect the liver from NAFLDrelated impairment by their upregulatory effect on both LPCs and LPCOs.
HMRS or
In contrast to its correlation with LPCs and LPCOs upregulation, the G/G genotype at PNPLA3 rs2294918 conferred significantly lower levels of PEs in the NAFLD patients compared to those with the A/A + A/G ge notype. A similar decrease in serum PE 34:0 was found in these NAFLD patients in association with the A/A genotype at PNPLA3 rs139051. Recent studies have highlighted a growing increase in PE concentration during progression of NAFLD (healthy control < simple steatosis < NASH) [38] . Nevertheless, individuals carrying the Val175Met variant allele of PE Nmethyltransferase (PEMT), which inhibits PE to PC conversion, show high susceptibility to NASH [39] . PEMT / mice also suffer from NASH after being fed a choline-deficient or highfat diet [40, 41] . Thus, PNPLA3 rs139051 and rs2294918 represent a novel layer of genetic regulation that down regulates the harmful components of lipidomics.
Metabolically, LPCs are catabolized into PCs by the lysophosphatidylcholine acyltransferase 1/2/4 [32] . Glycerophosophocholine, the lysoplasmalogenase dependent catalysate of LPCOs, serves as another precursor of PCs [36, 37] . As a result, the upregulation of LPCs and LPCOs, together with the downregulation of PEs, may lead to an increased ratio of PC to PE in NAFLD patients with the A/A genotype at PNPLA3 rs139051 and/or G/G at PNPLA3 rs2294918. Acting as the major source of serum phospholipids, hepatic PCs and PEs play an essential part in the integrity of cellular and organelle membranes [41, 42] . An abnormally low molar ratio of PC/PE has been linked to steatohepatitis due to its induction of membrane leakage [43] . On the contrary, administration of polyene PC prevents patients from hepatic injury, with an improvement in PC/PE ratio [44] . Because of the antioxidant propensity of plasmalogen, LPCO deficiency is responsible for additional effects of NASH that sensitize patients to reactiveoxygen speciesdependent peroxidation, and successive lobular inflammation [45, 46] . An inflammationattenuating effect of PNPLA3 rs139051 and rs2294918 is then proposed on the basis of LPCs and LPCOs augmentation.
Indeed, our experimental observations relating to NAFLD patients revealed that an increase in LPCs and LPCOs significantly correlated with an attenuation of hepatic inflammation. Both high-level LPCs/LPCOs and lowgrade lobular inflammation characterized patients with the A/A genotype at PNPLA3 rs139051 and/or the G/G genotype at rs2294918. However, pathological characteristics other than hepatic inflammation, including hepatocyte steatosis, ballooning, and liver Similar, yet mild, amelioration of lobular inflammation occurred in NAFLD patients carrying the G/G rather than other genotypes at PNPLA3 rs2294918.
In conclusion, PNPLA3 SNPs reflect an important genetic basis of lipidomic characteristics in NAFLD patients, with the focus on phospholipid metabolite profile. The A/A genotype at PNPLA3 rs139051 exerts an upregulatory effect on serum LPCs and LPCOs. Both the genotype of PNPLA3 rs139051 and the increased levels of LPCs/LPCOs share an association with the lowgrade lobular inflammation of NAFLD. PNPLA3 rs139051, therefore, may underlie the infla mmatory progress of NAFLD by its modulation of the phospholipid metabolite profile.
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